Dr. Torley joined Halozyme in January 2014 as President and Chief Executive Officer. Quickly after joining Halozyme, she restructured the company to focus on oncology and has since spearheaded eight large deals with big pharma partners surrounding the company’s ENHANZE drug delivery technology. Behind Dr. Torley’s work is the goal to develop and advance therapies that enable meaningful therapeutic improvements for patients. Throughout her career, Dr. Torley has led several successful global product launches, including Kyprolis®, Prolia®, Sensipar®, and Miacalcin®. Before joining Halozyme, Dr. Torley served as Executive Vice President and Chief Commercial Officer for Onyx Pharmaceuticals. Dr. Torley is a member of the board of directors for Quest Diagnostics. She is also a member of the Health Section Governing Board of BIO, the Biotechnology Innovation Organization, and chair of BIO’s Workforce Development, Diversity and Inclusion committee.
Dr. Torley brings extensive commercial and business experience as well as an extensive knowledge of the biotechnology industry. Before joining the industry, Dr. Torley practiced medicine as a rheumatologist at the Royal Infirmary in Glasgow, Scotland. She received her Bachelor of Medicine and Bachelor of Surgery degrees (M.B. Ch.B.) from the University of Glasgow and is a Member of the Royal College of Physicians (M.R.C.P).